Inventor

Philip Wilson Howard

Inventor

London, GB

Overview

2003–2021

Patent span

Human necessities

Primary field (CPC A)

Patents· 80 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Pprimary

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations29%

C07DHeterocyclic compounds24%

A61KPreparations for medical, dental or toiletry purposes22%

C07KPeptides12%

Y02PClimate change mitigation technologies in the production or processing of goods6%

Y02ATechnologies for adaptation to climate change4%

C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium1%

C07HSugars1%

C09KMaterials for miscellaneous applications, not provided for elsewhere0%

C40BCombinatorial chemistry0%

PatentTitleYear

10,994,023Pyrrolobenzodiazepines and conjugates thereof2021 10,799,595Pyrrolobenzodiazepine conjugates2020 10,799,596Pyrrolobenzodiazepine-antibody conjugates2020 10,780,181Pyrrolobenzodiazepine-antibody conjugates2020 10,780,096Pyrrolobenzodiazepine-antibody conjugates2020 10,751,346Pyrrolobenzodiazepine--anti-PSMA antibody conjugates2020 10,736,903Pyrrolobenzodiazepine-anti-PSMA antibody conjugates2020 10,722,594Pyrrolobenzodiazepine-anti-CD22 antibody conjugates2020 10,695,439Pyrrolobenzodiazepine conjugates2020 10,695,433Pyrrolobenzodiazepine-antibody conjugates2020 10,646,584Pyrrolobenzodiazepines and conjugates thereof2020 10,576,164Pyrrolobenzodiazepines and conjugates thereof2020 10,561,739Targeted pyrrolobenzodiazapine conjugates2020 10,543,279Pyrrolobenzodiazepine conjugates and their use for the treatment of cancer2020 10,533,058Peptidomimetic compounds and antibody-drug conjugates thereof2020 10,478,509Anti-DLL3 antibody drug conjugates for treating cancer2019 10,420,777Pyrrolobenzodiazepines and conjugates thereof2019 10,392,393Pyrrolobenzodiazepines2019 10,335,497Pyrrolobenzodiazepines and conjugates thereof2019 10,329,352Pyrrolobenzodiazepines and targeted conjugates2019 10,328,084Pyrrolobenzodiazepines and targeted conjugates2019 10,188,746Pyrrolobenzodiazepines and conjugates thereof2019 10,029,018Pyrrolobenzodiazepines and conjugates thereof2018 10,017,580Humanized anti-Tn-MUC1 antibodies and their conjugates2018 10,010,624Pyrrolobenzodiazepine-antibody conjugates2018 9,968,687Anti-DLL3 antibody drug conjugates2018 9,956,299Pyrrolobenzodiazepine--antibody conjugates2018 9,956,298Pyrrolobenzodiazepines and conjugates thereof2018 9,950,078Pyrrolobenzodiazepine-antibody conjugates2018 9,931,414Pyrrolobenzodiazepine-antibody conjugates2018 9,931,415Pyrrolobenzodiazepine-antibody conjugates2018 9,919,056'Pyrrolobenzodiazepine-anti-CD22 antibody conjugates'2018 9,889,207'Pyrrolobenzodiazepines and conjugates thereof'2018 9,821,074'Pyrrolobenzodiazepines and conjugates thereof'2017 9,745,303'Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation'2017 9,732,084'Pyrrolobenzodiazepines used to treat proliferative diseases'2017 9,713,647'Pyrrolobenzodiazepines and targeted conjugates'2017 9,707,301'Pyrrolobenzodiazepines and targeted conjugates'2017 9,649,390'Pyrrolobenzodiazepines and conjugates thereof'2017 9,624,227'Unsymmetrical pyrrolobenzodiazepine-dimers for treatment of proliferative diseases'2017 9,592,240'Targeted pyrrolobenzodiazapine conjugates'2017 9,567,340'Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases'2017 9,562,049'Pyrrolobenzodiazepines and conjugates thereof'2017 9,526,798'Pyrrolobenzodiazepines and targeted conjugates'2016 9,415,117'Pyrrolobenzodiazepines and conjugates thereof'2016 9,399,641'Pyrrolobenzodiazepines as unsymmetrical dimeric PBD compounds for inclusion in targeted conjugates'2016 9,399,073'Pyrrolobenzodiazepines'2016 9,387,259'Pyrrolobenzodiazepines and targeted conjugates'2016 9,388,187'Pyrrolobenzodiazepines'2016 9,387,258'Pyrrolobenzodiazepines and targeted conjugates'2016 9,376,440'Pyrrolobenzodiazepines as antiproliferative agents'2016 9,321,774'Pyrrolobenzodiazepines'2016 9,266,894'Pyrrolobenzodiazepines as unsymmetrical dimeric PBD compounds for inclusion in targeted conjugates'2016 9,242,013'Targeted pyrrolobenzodiazapine conjugates'2016 9,102,704'Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines'2015 8,940,733'Unsymmetrical pyrrolobenzodiazepine-dimers for treatment of proliferative diseases'2015 8,829,184'Intermediates useful for the synthesis of pyrrolobenzodiazepines'2014 8,697,688'Pyrrolobenzodiazepines used to treat proliferative diseases'2014 8,637,664'Alkyl 4- [4- (5-oxo-2,3,5, 11a-tetrahydo-5H-pyrrolo [2, 1-c] [1,4] benzodiazepine-8-yloxy)-butyrylamino]-1H-pyrrole-2-carboxylate derivatives and related compounds for the treatment of a proliferative disease'2014 8,633,185'Pyrrolobenzodiazepines'2014 8,592,576'Unsymmetrical pyrrolobenzodiazepine-dimers for treatment of proliferative diseases'2013 8,501,934'Pyrrolobenzodiazepines'2013 8,487,092'Pyrrolobenzodiazepines'2013 7,834,005'Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto'2010 7,741,319'11-hydroxy-5h-pyrrolo[2,1-c][1,4] benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepines'2010 7,704,924'Library of compounds comprising pyrrolobenzodiazepine moieties'2010 7,612,062'Pyrrolobenzodiazepines'2009 7,557,099'Pyrrolobenzodiazepines as key intermediates in the synthesis of dimeric cytotoxic pyrrolobenzodiazepines'2009 7,528,126'Pyrrolobenzodiazepines'2009 7,511,032'Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto'2009 7,429,658'Synthesis of protected pyrrolobenzodiazepines'2008 7,407,951'Pyrrolobenzodiazepines'2008 7,265,105'Pyrrolobenzodiazepines'2007 7,244,724'Pyrrolobenzodiazepines'2007 7,067,511'Pyrrolobenzodiazepines'2006 7,049,311'Pyrrolbenzodiazepines'2006 6,909,006'Cyclopropylindole derivatives'2005 6,747,144'Collections of compounds'2004 6,608,192'Collections of compounds'2003 6,562,806'Pyrrolobenzodiazepines'2003

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2003–2010Patents assigned to SPIROGEN LTD (17)· patent assignee history

2003–2010Based in Nottingham, GB· patent location history

2003–2006Based in University Park, GB· patent location history

2005–2020Based in London, GB· patent location history

2007–2010Based in St. Albans, GB· patent location history

2013–2020Patents assigned to HOWARD PHILIP WILSON (9)· patent assignee history

2013–2018Patents assigned to SPIROGEN SARL (9)· patent assignee history

2014–2020Patents assigned to SEATTLE GENETICS INC (12)· patent assignee history

2016–2021Patents assigned to MEDIMMUNE LTD (51)· patent assignee history

2018–2021Based in Cambridge, GB· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
MEDIMMUNE LTD	51	2016–2021
SPIROGEN LTD	17	2003–2010
SEATTLE GENETICS INC	12	2014–2020
HOWARD PHILIP WILSONself	9	2013–2020
SPIROGEN SARL	9	2013–2018

Locations

Location	Patents	Span
London, GB	47	2005–2020
Cambridge, GB	20	2018–2021
St. Albans, GB	6	2007–2010
Nottingham, GB	5	2003–2010
University Park, GB	2	2003–2006